Obstet Gynecol:计划与非计划剖宫产女性 术后阿片类药物消耗有差别吗?

2019-03-04 不详 网络

2019年2月,发表在《Obstet Gynecol》的一项研究比较了,计划与非计划剖宫产女性术后阿片类药物消耗情况。

2019年2月,发表在《Obstet Gynecol》的一项研究比较了,计划与非计划剖宫产女性术后阿片类药物消耗情况。

目的:考察住院患者剖宫产后每天摄入大量阿片类药物的相关特征。

方法:这是一项回顾性队列研究,纳入2015年1月1日至2015年12月31日,在一所独立机构中,所有使用吗啡进行神经轴麻醉的剖宫产个体。排除术前阿片使用障碍或慢性阿片药物使用女性。提取社会人口统计学数据、合并症、抗焦虑药或抗抑郁药物的使用、吸烟史、非阿片类药物使用、产时和剖腹产特征,以及阿片类摄入的数据(转化为吗啡毫克当量)。研究者将大量阿片类使用定义为每天阿片类药物的平均摄入量,标准化为术后住院时间(排除术后首个24h用以解释神经轴吗啡),高于所有阿片类摄入的75%。研究者使用多变量Poisson回归,根据是否计划剖宫分层分析,考察大量阿片类摄入的特征。

结果:在进行剖宫产的949例女性中,平均(SD)和中位(四分位间距)每天阿片类摄入分别为48.6(22.8)和44.6(36.6~66.6)吗啡毫克当量。在大量阿片类药物摄入女性中,平均(SD)和中位(四分位间距)每天阿片类摄入分别为78.8(8.5)和78.3(72.9~83.5)吗啡毫克当量。计划与非计划剖宫产术女性阿片类大量摄入相似。大量阿片类摄入与非大量阿片类摄入女性的社会人口统计学特征相似。无论是计划还是非计划剖宫产女性,社会人口统计学、产前或产时特征均与阿片类大量摄入不相关。

结论:四分之一接受剖宫产的女性,每天的阿片类药物的摄入量等同于每天摄入10片5 mg羟考酮。计划与非计划剖宫产术女性无大量阿片类药物摄入相关特征。了解剖宫产后阿片类药物的摄入是管理女性术后疼痛,降低阿片类药物暴露,降低长期阿片类药物使用疾病风险的关键。

原始出处:

Prabhu M, Dolisca S, Wood R, et al. Postoperative Opioid Consumption After Scheduled Compared With Unscheduled Cesarean Delivery. Obstet Gynecol. 2019 Feb;133(2):354-363. doi: 10.1097/AOG.0000000000003087.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2011405, encodeId=6ec220114056e, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Sep 08 10:39:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044090, encodeId=cfda204409006, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Aug 08 16:39:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253086, encodeId=4f421253086ad, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Wed Mar 06 05:39:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309127, encodeId=1434130912efd, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Wed Mar 06 05:39:00 CST 2019, time=2019-03-06, status=1, ipAttribution=)]
    2019-09-08 yhy100200
  2. [GetPortalCommentsPageByObjectIdResponse(id=2011405, encodeId=6ec220114056e, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Sep 08 10:39:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044090, encodeId=cfda204409006, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Aug 08 16:39:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253086, encodeId=4f421253086ad, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Wed Mar 06 05:39:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309127, encodeId=1434130912efd, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Wed Mar 06 05:39:00 CST 2019, time=2019-03-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2011405, encodeId=6ec220114056e, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Sep 08 10:39:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044090, encodeId=cfda204409006, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Aug 08 16:39:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253086, encodeId=4f421253086ad, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Wed Mar 06 05:39:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309127, encodeId=1434130912efd, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Wed Mar 06 05:39:00 CST 2019, time=2019-03-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2011405, encodeId=6ec220114056e, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Sep 08 10:39:00 CST 2019, time=2019-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2044090, encodeId=cfda204409006, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Aug 08 16:39:00 CST 2019, time=2019-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253086, encodeId=4f421253086ad, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Wed Mar 06 05:39:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309127, encodeId=1434130912efd, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Wed Mar 06 05:39:00 CST 2019, time=2019-03-06, status=1, ipAttribution=)]
    2019-03-06 lhlxtx

相关资讯

Anaesthesia:剖宫产腰麻后低血压时血管活性药物的使用:有金标准了吗

腰麻是剖宫产最常用的麻醉方法,然而腰麻后低血压发生率高达71%。低血压可导致产妇发生恶心、呕吐和头晕,严重者可因子宫胎盘血流减少进而导致胎儿缺氧和酸中毒。如何预防或治疗腰麻导致的低血压是产科麻醉最关注的热点问题之一。早先认为低血压发生的原因主要是由主动脉下腔静脉受压导致静脉回流、心室充盈、每博量和心输出量减少导致。然而采用静脉输注液体的方案来纠正低血压效果甚微。而目前认为由腰麻后交感神经阻滞导

ASA:刨宫产刀口长度多长才合适?

短期和长期剖宫产手术切口与分娩后疼痛增加有关,在ANESTHESIOLOGY 2017年会上提交了一项研究。根据研究结果,作者建议剖宫产切割长度的最佳范围为12至17厘米(约4.5 - 6.5英寸),并建议尽可能不进行更短或更长的切口。

Anesth Analg:间歇快速静脉注射去氧肾上腺素和去甲肾上腺素防治剖宫产术中腰麻低血压的比较:随机对照试验

目前去氧肾上腺素 (PE)是预防和治疗剖宫产 (CD)术中腰麻低血压的首选血管升压药,然而,其使用常引起反射性心动过缓。去甲肾上腺素 (NE)因治疗低血压的同时可维持心率(HR)稳定,成为剖宫产术中的替代性血管升压药。新近研究表明,与PE相比,NE输注效果更好,但剖宫产术中快速注射等效剂量PE和NE的研究尚无报道。本研究假设,间歇快速注射等效剂量的PE及NE预防和治疗腰麻低血压时,与PE相比,NE

Anesth Analg:预输入胶体联合晶体液与单独输入晶体液在腰麻下剖宫产术中的比较:随机对照试验

与单独补充1000ml晶体液相比,500ml胶体液联合500ml晶体液并没有减少麻黄碱的使用量或改善产妇的结局。但在剖宫产术前和剖宫产术期间可靠地观察IVC,其直径随时间有明显变化并且在两组之间有差异。

这么多女明星选择剖宫产,那是她们不知道疤痕子宫的厉害!

关心娱乐圈八卦的人,就会发现一大批女明星不约而同地选择剖宫产生子,包括林心如、赵薇、刘涛、辣妹维多利亚、张柏芝、大小S等。似乎剖宫产就是快速、方便、无公害的生产方式。